Risen Pharma has entered into a comprehensive strategic cooperation agreement with the Shanghai Center for Infectious Diseases and Immune Innovation.

Risen Pharma has entered into a comprehensive strategic cooperation agreement with the Shanghai Center for Infectious Diseases and Immune Innovation.

Release time：2024-11-13 Click：65

Hot News

PI3K-α inhibitor RP903 tablets have been approved for two additional PROS pediatric rare disease clinical trials.
Risen Pharma and Maiwei Biotech have signed a licensing agreement to jointly promote the development of drugs in the field of bone health.
Risen's innovative KRAS drug research result has been selected for presentation at the AACR Annual Meeting 2024 in San Diego, California!
Risen found status in the "2023 Hurun Global Cheetah Enterprise List"
Congratulations! Risen successfully acquired Biosafety Laboratory level 2 (BSL-2) qualification.
Congratulations! Risen laned in “KPMG China Biotech Future Sector 50 Ranking”

Shanghai Zhangjiang R&D Center.

Suzhou Industrial Park R&D Center.

Copyright 2022 Risen(Shanghai) Pharma Tech Co., Ltd. All Rights Reserved 沪ICP备16020731号-1 Design by：yushangweb